TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01270958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avamys aqueous nasal spray 110mcg
Description: At the visit 1, subjects who fulfill the inclusion criteria are eligible to be included in the group to self-administer intranasal treatment of fluticasone furoate aqueous nasal spray 110 mcg once daily for 6 week. The subjects are instructed to administer two sprays from the device into each nostril once daily every morning. Administration of the dose will be performed by alternately spraying one spray to each nostril followed by a second spray to each nostril. Subjects will not be permitted to take any anti-allergy or rhinitis medication during the screening or treatment period.~Throughout the study, subjects will document their study drug administration/compliance, any medical conditions experienced, and any concomitant medications taken.
Study: NCT01812070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Study: NCT03915912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: The study intervention consists of seven mindfulness sessions (six 1-hour telephone sessions and one 1-hour in-person session). The six weekly telephone-based mindfulness sessions will occur in a one-on-one format and will be followed by one in-person, one-on-one session, which will occur at the post-chemoradiation standard of care clinic visit.
Study: NCT03470857

Intervention type: DIAGNOSTIC_TEST
Intervention: Patients
Description: The FDG PET/CT imaging will be performed as part of typical medical procedures related to the diagnosis and monitoring of cancers at the Oncology Center in Bydgoszcz, Poland
Study: NCT03595384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Soccer-based adaptation to the DPP
Description: Participants will complete online education modules during an initial 12 week conditioning phase where they will participate in soccer drills and other fitness routines (two 1-hour sessions per week). At the 12 week mark participants will transition onto a soccer league team for the following 12 weeks where they will continue to complete online modules and meet with the soccer coach monthly.~During the soccer sessions and games participants will be fitted with a wearable soccer-specific device to measure how much they move and their heart rate. In addition, they will also be asked to wear a Garmin fitness tracker for the duration of the study to measure steps and moderate and vigorous activity.~The online education will be a version of the Diabetes Prevention Program and can be completed on a phone or computer with internet access.
Study: NCT00860990

Intervention type: OTHER
Intervention: Completion of GI quality of life survey
Description: Subjects are asked to complete a survey related to bowel care and its effects on various variables related to quality of life.

Intervention type: OTHER
Intervention: Completion of GI quality of life survey
Description: Subjects are asked to complete a survey related to bowel care and its effects on various variables related to quality of life.
Study: NCT03729843

Intervention type: RADIATION
Intervention: CBCT and intraoral digital radiography
Description: Simulated periodontal bone defects will be measured by 2 techniques: group I detected and measured using CBCT and group II intraoral digital radiography and all the measurements will be compared with the gold standard real measurements on the dry jaws
Study: NCT04668092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional dry needling
Description: functional dry needling applied to hamstring for 1 minute and post interventional data collected
Study: NCT06379438

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (indocyanine green+laser)
Description: Photodynamic therapy with indocyanine green
Study: NCT01052519

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Goal directed fluid therapy
Description: Fluid will be administered to reach maximal stroke volume during the intraoperative period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Goal directed fluid therapy
Description: Fluid will be administered to reach maximal stroke volume during the intraoperative period.
Study: NCT03482128

Intervention type: DEVICE
Intervention: Coagulation management guided by SONOCLOT
Description: Application of blood products guided by SONOCLOT measurements

Intervention type: DEVICE
Intervention: Standard coagulation management
Description: Application of blood products based on clinical experience of the anesthesiologist in charge
Study: NCT00357422

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operation
Description: No drug needed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous ethanol injection therapy
Description: 99% ethanol, 2-4cc per one session, two to three sessions per single procedure for one week
Study: NCT01249963

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: T-Diet plus Atémpero
Description: T-Diet plus Atémpero is a complete normocaloric and normoproteic enteral nutrition product for the dietary management of patients with mild acute pancreatitis.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AlitraQ (Abbott)
Description: AlitraQ is a nutritional product for patients with impaired gastrointestinal function.For oral or tube nutrition. Enriched with glutamine and arginine.
Study: NCT03174613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC51-0255
Description: 0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
Study: NCT01095341

Intervention type: OTHER
Intervention: No intervention performed

Intervention type: OTHER
Intervention: No intervention performed
Study: NCT00738829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose escalation stage: starting dose 2.5mg/d, dose escalation via 5/10/15/20/25 mg/d every 28 days if no dose-limiting toxicity.~During maintenance stage dosing on days 1-28 for max. 6 months at maximum tolerated dose reached during dose escalation stage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2 i.v. d1-3 or 40 mg/m2 po d1-3 every 28 days for 6 cycles during dose escalation stage.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Dose escalation stage: 375 mg/m2 i.v. d4 Cycle 1, 500 mg/m2 i.v. d1 Cycles 2-6.~Maintenance stage: 375 mg/m2 i.v. at 2/4/6 months after end of escalation stage.
Study: NCT02646150

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Perfusion Imaging
Study: NCT03803202

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP3772
Description: Participants received a single dose of ASP3772 (ASP3772 low dose, ASP3772 medium dose and ASP3772 high dose) intramuscularly
Study: NCT02278315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-131-CLR1404
Description: Single IV dose of I-131-CLR1404, increased/decreased by cohort
Study: NCT03803202

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP3772
Description: Participants received a single dose of ASP3772 (ASP3772 low dose, ASP3772 medium dose and ASP3772 high dose) intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP3772
Description: Participants received a single dose of ASP3772 (ASP3772 low dose, ASP3772 medium dose and ASP3772 high dose) intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP3772
Description: Participants received a single dose of ASP3772 (ASP3772 low dose, ASP3772 medium dose and ASP3772 high dose) intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP3772
Description: Participants received a single dose of ASP3772 (ASP3772 low dose, ASP3772 medium dose and ASP3772 high dose) intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP3772
Description: Participants received a single dose of ASP3772 (ASP3772 low dose, ASP3772 medium dose and ASP3772 high dose) intramuscularly

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: Participants received a single dose of PCV13 intramuscularly.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: Participants received a single dose of PCV13 intramuscularly.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Participants received a single dose of PPSV23 intramuscularly.
Study: NCT02224638

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TheraHoney HD
Description: Honey

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SkinTegrity
Description: Hydrogel
Study: NCT02994095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pilot Study
Description: Trained community health agents used Motivational Interviewing-based counseling and action planning in monthly home visits with adults with diabetes
Study: NCT00722709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: In the treatment arm patients will receive 10mls 0.75% ropivacaine diluted to 50mls with saline immediately before closure.~At closure, two small 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump (On-Q pain buster). This pump will contain 270mls of 0.2% ropivacaine. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: In the placebo arm patients will receive 50 ml 0.9% saline into the peritoneum soon after the creation of the laparotomy.~At closure, two 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump on-Q pain buster). This pump will contain 0.9% saline. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal.
Study: NCT02807844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
Study: NCT02278315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg dexamethasone orally once weekly for up to 12 weeks
Study: NCT02807844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
Study: NCT02278315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-131-CLR1404
Description: Multiple IV dose of I-131-CLR1404, increased/decreased by cohort
Study: NCT00750230

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NEM
Description: see Treatment Arm
Study: NCT02807844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
Study: NCT01553071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide (4-HPR) plus Intravenous Safingol
Description: A course for this study is defined as the 5 days of treatment with Fenretinide (4-HPR) plus Safingol followed by 16 days of rest. A course is repeated every 21 days if there is no clinical evidence of disease progression for a maximum of six 5-day infusions.~Days 1-5 of every cycle: Day 1 Fenretinide (4-HPR) intravenous emulsion: 600 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Day 2 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Days 3-5 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 continuously for 3 days Days 8 and 15 : Weekly blood draw to monitor side effects requires a clinic visit for approximately 1 hour Days 6,7,9-14, 16-21 Rest and monitor side effects.
Study: NCT01198821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (g/kg/day)
Description: Dose Escalation - Level 1: 0.3, Level 2: 0.5, Level 3: 0/7, Level 4: 1.0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine (mg/m²)
Description: Dose Escalation - Level 1: 1000, Level 2: 1000, Level 3: 1000, Level 4: 1000
Study: NCT03154671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric assessment and management
Description: Each participant will receive a comprehensive geriatric assessment at baseline. Based on the issues identified, a tailored care plan will be developed with the participant to address the issues identified.
Study: NCT04631315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate Ophthalmic Emulsion 0.05%
Description: 1 drop, 2 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, once a day for the next 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate 1% Phenylephrine hydrochloride 0,12% ophthalmic solution
Description: 1 drop, 4 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, twice a day for the next 2 weeks.
Study: NCT04188990

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional dietary intervention
Description: The intervention will be carried out by the Endocrinology and Nutrition Service of hospital 1, where the type of therapeutic action to be developed will be established (Dietary advice, Oral Nutritional Supplementation (SNO), Enteral Feeding or Parenteral Nutrition). The Total Calorie Balance, calories from feeding or with Oral Nutritional Supplementation (ONS), enteral, parenteral, and protein intake will be recorded. The steps to be taken are the following: A.-In patients with preserved oral intake capacity apply the most appropriate dietary measures in each case. B.-If the oral route is contraindicated, it will be assessed if it is possible to use the gastrointestinal tract and enteral nutrition will begin until the patient recovers the oral intake capacity. C.-If the use of the gastrointestinal tract is not indicated, parenteral nutrition will be assessed until digestive function is restored.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: By demand
Description: In the By demand arm, it is by clinical judgement of the doctor responsible of each patient that can be demanded a nutritional intervention to the nutrition unit of the center's endocrinology service that will judge the type of intervention. This is their usual care right now

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Usual current care
Description: In th Usual care arm, there is no explicit nutritional intervention performed at this time for those patients and, therefore, their usual regular nutritional care will be provide
Study: NCT04131985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spina Block
Description: After the C7 spinous protrusion is prepared as sterile as T10, the erector spina muscle is seen at the T7 level on the same side as the hernia with the convex probe and block is applied with 0.25% bupivacaine (20 cc).
Study: NCT03487393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic facial nerve stimulation
Description: Magnetic stimulation of facial nerve.
Study: NCT02584413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: -Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium contrast
Description: -Standard of care
Study: NCT03788863

Intervention type: DRUG
Intervention: Diflucortolone valerate (BAY866146)
Description: Follow clinical administration
Study: NCT03663140

Intervention type: DIAGNOSTIC_TEST
Intervention: gingival crevicular fluid (GCF) and peri-implant sulcular fluid(PISF) collection
Description: GCF/PISF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva.

Intervention type: DIAGNOSTIC_TEST
Intervention: gingival crevicular fluid (GCF) and peri-implant sulcular fluid(PISF) collection
Description: GCF/PISF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva.

Intervention type: DIAGNOSTIC_TEST
Intervention: gingival crevicular fluid (GCF) and peri-implant sulcular fluid(PISF) collection
Description: GCF/PISF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva.

Intervention type: DIAGNOSTIC_TEST
Intervention: gingival crevicular fluid (GCF) and peri-implant sulcular fluid(PISF) collection
Description: GCF/PISF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva.

Intervention type: DIAGNOSTIC_TEST
Intervention: gingival crevicular fluid (GCF) and peri-implant sulcular fluid(PISF) collection
Description: GCF/PISF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva.

Intervention type: DIAGNOSTIC_TEST
Intervention: gingival crevicular fluid (GCF) and peri-implant sulcular fluid(PISF) collection
Description: GCF/PISF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva.
Study: NCT00776321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eprotirome
Study: NCT02537730

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bioclean MPS VII
Description: PHMB (Polyhexamethylene biguanide) base Disinfecting and Cleaning system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aosept Clearcare
Description: Hydrogen Peroxide Disinfecting and Cleaning system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: contact lens
Study: NCT00710892

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allodepleted T Cells
Description: Dose Level 1 = 1 x 10e6 T cells/kg; Dose Level 2 = 3 x 10e6 T cells/kg; Dose Level 3 = 1 x 10e7 T cells/kg.~Patients may be enrolled at the next dose level of T cells when all patients at the previous dose level have reached Day 42 post-T cell infusion without unacceptable toxicity.